{"entity":{"id":"lam561","kind":"drug","name":"LAM561","aka":[],"tldr":"LAM561 is an experimental small-molecule drug from Laminar Pharmaceuticals in phase 3 trials for glioma & glioblastoma, aimed at MET.","summary":"LAM561 is a small-molecule drug developed by Laminar Pharmaceuticals. Its target is MET (the sponsor names membrane lipids). The sponsor states: A hydroxylated lipid derivative that targets membrane lipids and induces cytocidal autophagy in cancer models; in Phase 2b/3 testing for newly diagnosed, MGMT-methylated glioblastoma. ClinicalTrials.gov describes the intervention as: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or r. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04250922 (LAM561 With RT and TMZ for Adults With Glioblastoma), in glioma & glioblastoma. The largest, NCT04250922, plans to enrol 144 participants (actual) with primary completion was scheduled for 2026-01-15 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LAM561","url":"https://clinicaltrials.gov/search?intr=LAM561"},{"label":"Sponsor page","url":"https://www.laminarpharma.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":["met"],"drugs":[],"companies":["laminar-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04250922","nct04299191"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"A hydroxylated lipid derivative that targets membrane lipids and induces cytocidal autophagy in cancer models; in Phase 2b/3 testing for newly diagnosed, MGMT-methylated glioblastoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lam561/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/"}],"trial":[{"id":"nct04250922","kind":"trial","name":"LAM561 With RT and TMZ for Adults With Glioblastoma","route":"/trials/nct04250922/"},{"id":"nct04299191","kind":"trial","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","route":"/trials/nct04299191/"}]}}